Ruth Ann Vleugels, MD, MPH, MBA

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.

An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.

Ruth Ann Vleugels, MD, MPH, MBA, provides insights on factors that inform JAK inhibitor treatment selection for patients with atopic dermatitis.

An expert on atopic dermatitis identifies patients who are good candidates for JAK inhibitors, highlighting contraindications for treatment.

An academic dermatologist describes how JAK inhibitors compare with other systemic treatments for atopic dermatitis and provides clinical insights on when to use which treatments.

Ruth Ann Vleugels, MD, MPH, MBA, provides an overview of oral JAK inhibitors approved for the treatment of atopic dermatitis and describes what makes them an attractive therapeutic option.